CAS 1633350-06-7

Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 4,5,6,7-tetrahydro-7-[1-(1-oxo-2-propen-1-yl)-4-piperidinyl]-2-(4-phenoxyphenyl)-

CAS : 1633350-06-7

Formule : C₂₇H₂₉N₅O₃

Degré de pureté : 99%

Couleur et forme : Solid

Masse moléculaire : 471.5509

Ref: IN-DA001U1B

(±)-Zanubrutinib

CAS : 1633350-06-7

(±)-Zanubrutinib

Degré de pureté : ≥98%

Masse moléculaire : 471.55g/mol

Ref: 54-BUP12738

(±)-Zanubrutinib

CAS : 1633350-06-7

Zanubrutinib is a small molecule drug that inhibits the activity of epidermal growth factor receptor (EGFR), which is involved in the development and progression of cancers. It also inhibits other targets, such as HER2+ breast cancer cells. Zanubrutinib has been shown to inhibit tumor growth in a xenograft model of skin cancer. The compound was well tolerated, with no signs of toxicity or adverse events observed at doses up to 400 mg/kg.

Formule : C₂₇H₂₉N₅O₃

Degré de pureté : Min. 95%

Masse moléculaire : 471.55 g/mol

Ref: 3D-IQC35006

(±)-Zanubrutinib

CAS : 1633350-06-7

(±)-Zanubrutinib ((±)-BGB-3111) is a potent and orally available Bruton's tyrosine kinase (Btk) inhibitor that demonstrates superior oral bioavailability,

Formule : C₂₇H₂₉N₅O₃

Degré de pureté : 99.09%

Couleur et forme : Solid

Masse moléculaire : 471.55

Ref: TM-TQ0039